Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Income (2020 - 2025)

Historic Net Income for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.

  • Xeris Biopharma Holdings' Net Income rose 10394.59% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7521.91%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.71% up from last year.
  • Xeris Biopharma Holdings' Net Income amounted to $621000.0 in Q3 2025, which was up 10394.59% from -$1.9 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Net Income high stood at $621000.0 for Q3 2025, and its period low was -$50.8 million during Q4 2021.
  • For the 5-year period, Xeris Biopharma Holdings' Net Income averaged around -$18.2 million, with its median value being -$16.8 million (2023).
  • In the last 5 years, Xeris Biopharma Holdings' Net Income tumbled by 13237.41% in 2021 and then surged by 10394.59% in 2025.
  • Xeris Biopharma Holdings' Net Income (Quarter) stood at -$50.8 million in 2021, then soared by 74.54% to -$12.9 million in 2022, then dropped by 3.56% to -$13.4 million in 2023, then skyrocketed by 61.81% to -$5.1 million in 2024, then skyrocketed by 112.15% to $621000.0 in 2025.
  • Its Net Income was $621000.0 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.